Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP

Inclusion Criteria: * Subjects are between the ages of 18 to 80 years * Subjects have a minimum of 20 permanent teeth, excluding third molars * Subjects have been diagnosed with gingivitis or periodontitis (Stages I and II are based on the level of CAL and Bone Loss (BL). The diagnosis is Stage I if: (a) BL is less than 15% and (b) CAL is between 1-2mm. The diagnosis is Stage II if: (a) BL is between 15% and 33% and (b) CAL is between 3-4mm) * Subjects exhibit bleeding upon probing in \>20% of sites * Subject is seen every 3 months for routine dental prophylaxis/periodontal maintenance * Subjects do not have a significant medical history or metabolic diseases (diabetes with A1C ≥ 7.0, pregnancy) * Subject is currently a non-smoker or has discontinued smoking at least 6 months prior to enrollment * Subject agrees to refrain from use of the following products: Peridex®, PerioGuard®, Listerine®, Cepacol®, Crest Pro-Health® rinse, Colgate Total® rinse, Colgate Total® toothpaste, Crest Pro Health® toothpaste, or any generic equivalent while participating in this study. Alcohol is not the active ingredient in any oral rinse product and does not produce a significant antibacterial effect * Subject is able to read and provide written informed consent * Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations * Subject agrees not to receive a dental "cleaning" (prophylaxis) while in the study * Subject must permanently reside in Arizona Exclusion Criteria: * Subject has significant medical history or poorly controlled/uncontrolled diabetes (as defined above) * Subject is pregnant * Subject has a medical condition that requires antibiotic premedication prior to dental treatment * Subject has taken antibiotics within 1 month of study enrollment * Subject who takes multiple medications and/or herbal and dietary supplements known to alter bleeding and exhibits/reports spontaneous gingival bleeding * Subject takes medications that may interfere with study results (eg. antibiotics, steroids, immunosuppressants, high dose aspirin (325+ mg/day), chemotherapy and/or radiation therapy for cancer). * Subject is a current smoker * Subject has a history of non-surgical or surgical periodontal therapy within 6 months of study participation * Subject has Stage III or IV periodontitis, Grade B or C * Subject is currently taking or in the past 28 days has taken another investigational drug or participated in other investigational studies that may impact study outcomes * Subject has not had a dental cleaning within six months prior to the start of the study